ACTRN12613000107729进行中（未招募）4 期
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer:A prospective controlled Trial from China
Changhai Hospital, Second Military Medical University0 个研究点目标入组 100 人开始时间: 2013年1月29日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 40 Years 至 80 Years（—）
- 性别
- Male
入选标准
- •.Inclusion Criteria (run-in period):
- •1)Histologically confirmed adenocarcinoma of the prostate
- •2)T1-T4, metastatic (M1) prostate cancer, T1-T4, non-metastatic (M0), N+ prostate cancer
- •.Inclusion criteria to the randomised period:
- •All patients recruited received the LHRHa goserelin acetate(Zoladex 3.6mg) subcutaneously every 28 days and bicalutamide(Casodex 50mg) orally once daily for 8 months(run in) before randomization. Patients in whom PSA decreased to less than 4.0ng/ml were randomized to IAD or CAD.
排除标准
- •.Exclusion Criteria (run-in period):
- •Any previous or concurrent treatment of prostate cancer, except TURP, 5-alpha reductase inhibitor, radical prostatectomy or radiotherapy Any medication/treatment affecting sex hormone status
- •.Exclusion Criteria:
- •Patients in whom prostate specific antigen decreased to no less than 4ng/ml were excluded
研究者
相似试验
招募中
不适用
atural Course of Hot Flash Symptoms in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer – a Pilot Investigation.atural course of hot flashes in men with prostate cancer, receiving ADT for the first time.Natural course of hot flashes in men with prostate cancer, receiving ADT for the first time.Cancer - ProstateACTRN12613000566730A/Professor Henry Woo20
进行中（未招募）
Unknown
Testing the addition of new treatments to standard treatment in prostate cancer that has spread to other areas of the bodyMetastatic hormone-sensitive prostate cancerCancerISRCTN66357938niversity College London4,914
进行中（未招募）
1 期
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigeMedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic prostate cancerEUCTR2018-004853-26-FITurku University Hospital35
进行中（未招募）
1 期
The effect of androgen deprivation therapy on prostate specific membrane antigen (PSMA)Prostate cancerEUCTR2017-002345-29-FITurku University Hospital5
招募中
不适用
To determine whether androgen deprivation therapy or androgen blockage therapy upregulates receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans for men with castrate resistant prostate cancer.Metastatic Prostate CancerACTRN12617001116314St Vincent's Hospital, Sydney20